Summary
- Profile Type
- Business Offer
- POD Reference
- BOFR20231102008
- Term of Validity
- 2 November 2023 - 1 November 2025
- Company's Country
- France
- Type of partnership
- Commercial agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- The French SME has developed a blood-based test to predict patient response to a gemcitabine-based first-line treatment for pancreatic cancer. The blood sample is collected during a visit to the oncologist before any treatment or surgery. The result is delivered within a week. This test is distributed in France, Germany and the UK. The SME is interested in establishing cooperation with distributors in Italy, Switzerland, Austria, Czech Republic, Finland, Sweden, Denmark, Netherlands and Spain.
- Full Description
-
Pancreatic cancer is one of the cancers with the poorest prognosis, with a 5-year survival rate of 5-15%. Diagnosis generally occurs at an advanced stage of the disease, and for about 80% of cases the tumor cannot be operated on, making the disease incurable. Thus, any therapeutic solution for these non-operable patients is aimed at increasing their lifespan.
For remainder patients, biomarkers used for diagnosis/prognosis and to monitor the response to treatment, such as age, carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA), are not adequate for a right management of patients, partly due to low sensitivity/specificity.
In this context, prescribing the right therapy to the right patient in 1st line is a key-point and a strong advantage to extend the patient's lifespan while maintaining a satisfactory or acceptable quality of life during treatment.
Nevertheless, due to the lack of appropriate tools, treatments are today prescribed according to the expertise and beliefs of the oncologists.
The French SME provides the first blood-based diagnostic that enables to predict the response to a gemcitabine-based first-line treatment for patients suffering from locally advanced or metastatic, non-surgical pancreatic adenocarcinoma (PDAC). This CE-marked molecular diagnostic, based on a patented gene-blood signature, identifies PDAC patients who will benefit from gemcitabine as 1st line therapy, avoiding the prescription of another treatment, less effective, more toxic and more expensive.
The use of this innovative In-Vitro Diagnostic (IVD) will be part of a consultation (pre-therapeutic assessment) already planned in the patient's current care management.
Easy to handle, it requires only 2.5ml blood sample before starting the patient's 1st line chemotherapy. From this liquid biopsy, this IVD measures the expression levels of several genes (mRNA) using real-time PCR technology. Standard operating procedures of real-time PCR and associated platforms are widely used in laboratories and are part of the Gold Standard. The data issued from a PCR analysis are treated by a specific and proprietary algorithm within few seconds.
Patients with a clinical benefit response identified by this IVD have a significantly longer overall survival: 10.4 months for the positive group versus 4.8 months for the negative group.
This IVD is produced by the French SME according to the CE-mark criteria, and distributed in France, Germany and United Kingdom by a French distributor. The French SME is looking for distributors and partners with experience in diagnostics business and the commercialization of products dedicated to digestive cancers.
The French SME is interested in establishing cooperation with distributors in Italy, Switzerland, Austria, Czech Republic, Finland, Sweden, Denmark, Netherlands and Spain.
This CE-marked molecular diagnostic represents the first innovative step of precision medicine in PDAC care - Advantages and Innovations
-
> This IVD is a blood-based test, avoiding to perform a tumor biopsy. It is the 1st blood-based predictive diagnostic in pancreatic cancer.
> This IVD is based on PCR technology, and in particular on the LC480 instrument from Roche Diagnostics, a material widely used in private/hospital laboratories.
> The routine use of this IVD by healthcare actors involved in PDAC treatment will generate real societal and economic impacts:
• Identifying the sub-population of PDAC patients who will benefit from a gemcitabine-based therapy as 1st line treatment,
• Avoiding the prescription of ineffective, toxic and expensive therapies,
• Providing a better quality of life for patients identified by this IVD (gemcitabine is one of the least toxic therapies),
• Limiting the cost of care (gemcitabine = one of the least expensive therapies). - Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR granted
Partner Sought
- Expected Role of a Partner
-
The French SME is looking for distributors and partners with experience in diagnostics business and the commercialization of products dedicated to digestive cancers.
The test will be used by professionals in diagnostic laboratories or hospitals.
The French SME is interested in establishing cooperation with distributors in Italy, Switzerland, Austria, Czech Republic, Finland, Sweden, Denmark, Netherlands and Spain. - Type and Size of Partner
- SME 11-49
- SME 50 - 249
- Big company
- Type of partnership
- Commercial agreement
Dissemination
- Technology keywords
- 06001003 - Cytology, Cancerology, Oncology
- 06003002 - Gene Expression, Proteome Research
- 06002002 - Cellular and Molecular Biology
- 06001005 - Diagnostics, Diagnosis
- Market keywords
- 05001002 - In-vitro diagnostics
- 04016 - Population genetics
- 05005014 - Oncology
- 04015 - Gene Expression, Proteome Research
- Sector Groups Involved
- Health
- Targeted countries
- All countries
